Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9

Wu, Shan-Ying; Wang, Biao; Chen, Lifen; Xiong, Shuyuan; Zhuang, Fu-lian; Huang, Xiaohua; Wang, Meishui; Huang, Zugen

doi:10.3892/etm.2015.2650

Cited by 22 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore they showed that PRO treatment could reduce the rate of tumour growth and infiltration in vivo. A similar inhibition of the upregulation of MMP-2 and MMP-9 by PRO has also been reported in nasopharyngeal carcinoma [59], pancreatic cancer [50, 53], gastric adenocarcinoma [66], melanoma [106], prostate cancer [107] and of MMP-9 in medulloblastoma [108] and infantile hemangioma [109–110]. …”

Section: Mechanisms Of Actionsupporting

confidence: 69%

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Pantziarka

Bouche

Sukhatme³

et al. 2016

ecancer

View full text Add to dashboard Cite

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

show abstract

Section: Mechanisms Of Actionsupporting

confidence: 69%

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Pantziarka

Bouche

Sukhatme³

et al. 2016

ecancer

View full text Add to dashboard Cite

show abstract

“…Wu et al. (2015) investigated the effectiveness of propranolol treatment in IH and changes in the serum levels of VEGF, bFGF, and MMP‐9. The authors examined 129 cases, 97 of which were treated with oral propranolol; 32 received no treatment.…”

Section: Mechanism Of Action Of Beta‐blockersmentioning

confidence: 99%

“…The authors speculated that the effects of propranolol on IH might be due to the reduction of VEGF and eNOS. Wu et al (2015) [ 48 ] investigated the effectiveness of propranolol treatment in IH and changes in the serum levels of VEGF, bFGF, and MMP-9. The authors examined 129 cases, 97 of which were treated with oral propranolol; 32 received no treatment.…”

Section: Mechanism Of Action Of Beta-blockersmentioning

confidence: 99%

Infantile hemangioma: pathogenesis and mechanisms of action of propranolol

Rotter

Oliveira

2017

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryInfantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 %. It is characterized by a proliferative rapid growth phase, which starts after a few weeks of life, followed by a slow regression phase. In IH cases that are potentially disfiguring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. Data source: The present study reviews published scientific articles available in reliable electronic databases. Selected were all studies that evaluated the pathogenesis of IH and the mechanisms of action of propranolol. Conclusions: The pathogenesis of IH has not been fully elucidated. Studies show that, in the proliferative phase of IH, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor and matrix metalloproteinases 2 and 9. In the regression phase, the levels of these factors decrease, whereas those of antiangiogenic factors, including tissue inhibitors of matrix metalloproteinases, increase. Since 2008, propranolol has become the drug of choice in the treatment of IH, targeting vascular tone, angiogenesis, and apoptosis. Current insights into the pathogenesis of IH allow for the development of new therapeutic strategies.

show abstract

“…Wu et al. (2015) untersuchten die Wirksamkeit der Therapie des IH mit Propranolol und die Veränderungen der Serumspiegel von VEGF, bFGF und MMP‐9. Die Autoren werteten 129 Fälle aus, 97 Patienten erhielten Propranolol p.o., 32 keine Behandlung.…”

Section: Wirkmechanismus Der Betablockerunclassified

Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol

Rotter

Oliveira

2017

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryInfantile hemangioma (IH) is the most common benign tumor of childhood, with a prevalence of 4 % to 10 %. It is characterized by a proliferative rapid growth phase, which starts after a few weeks of life, followed by a slow regression phase. In IH cases that are potentially disfiguring or life-threatening (10 % to 15 % of all cases), systemic therapy should be promptly initiated. Data source: The present study reviews published scientific articles available in reliable electronic databases. Selected were all studies that evaluated the pathogenesis of IH and the mechanisms of action of propranolol. Conclusions: The pathogenesis of IH has not been fully elucidated. Studies show that, in the proliferative phase of IH, there is an imbalance of angiogenic factors and an increase in the levels of vascular endothelial growth factor and matrix-metalloproteinases 2 and 9. In the regression phase, the levels of these factors decrease, whereas

show abstract

Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9

Cited by 22 publications

References 16 publications

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Infantile hemangioma: pathogenesis and mechanisms of action of propranolol

Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol

Contact Info

Product

Resources

About